30-Day Cardiac Event Monitor Belt for Recording Atrial Fibrillation After a Cerebral Ischemic Event (EMBRACE)
3. Oktober 2018 aktualisiert von: Dr. David Gladstone, Sunnybrook Health Sciences Centre
30-Day Cardiac Event Monitor Belt for Recording Atrial Fibrillation After a Cerebral Ischemic Event: A Randomized Controlled Trial
Atrial fibrillation is the most common cardiac cause of ischemic stroke.
Detecting atrial fibrillation after a stroke or TIA is critical because highly effective secondary stroke prevention therapy is available for individuals who are recognized to have atrial fibrillation.
However, atrial fibrillation is likely under-diagnosed after stroke and TIA because atrial fibrillation is often difficult to detect as it is frequently paroxysmal and asymptomatic, and patients do not routinely undergo prolonged screening.
The purpose of this study is to determine the diagnostic yield of a novel 30-day cardiac event monitor compared to a repeat 24-hour Holter monitor for detecting occult paroxysmal atrial fibrillation in patients with a recent ischemic stroke or TIA of undetermined etiology after completion of a standard clinical stroke work-up (including an initial negative Holter monitor.)
Studienübersicht
Status
Unbekannt
Intervention / Behandlung
Studientyp
Interventionell
Einschreibung (Voraussichtlich)
564
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
Alberta
-
Calgary, Alberta, Kanada
- Foothills Medical Centre
-
Edmonton, Alberta, Kanada
- Grey Nuns Hospital
-
Edmonton, Alberta, Kanada
- Walter C. Mackenzie Health Sciences Centre
-
-
British Columbia
-
Vancouver, British Columbia, Kanada
- Vancouver Hospital and Health Sciences Centre
-
Victoria, British Columbia, Kanada
- Vancouver Island Health Research Centre (VIHA)
-
-
Ontario
-
Hamilton, Ontario, Kanada
- Hamilton Health Sciences Centre
-
Kingston, Ontario, Kanada
- Kingston General Hospital
-
London, Ontario, Kanada
- London Health Sciences Centre
-
London, Ontario, Kanada
- Robarts Research Institute
-
Ottawa, Ontario, Kanada
- Ottawa Hospital Research Institute -The Ottawa Hospital
-
Thunder Bay, Ontario, Kanada
- Thunder Bay Regional HSC
-
Toronto, Ontario, Kanada
- St. Michael's Hospital
-
Toronto, Ontario, Kanada
- Sunnybrook Health Sciences Centre
-
Toronto, Ontario, Kanada
- UHN / Toronto Western Hospital
-
Toronto, Ontario, Kanada
- York Central Hospital
-
-
Quebec
-
Montreal, Quebec, Kanada
- Montreal General Hospital
-
Quebec City, Quebec, Kanada
- CHA-Hôpital de l'Enfant-Jesus
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
55 Jahre und älter (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion:
Diagnosis of the index event* made by a stroke specialist of an acute ischemic stroke or TIA (WHO definition) of undetermined etiology (cryptogenic) occurring within the previous 6 months (180 days).The event must be either:
- an embolic arterial ischemic stroke confirmed by neuroimaging; or
- a transient ischemic attack, defined as involving a focal unilateral motor deficit, speech/language deficit, or hemianopia, with symptom duration <24 hours (note: amaurosis fugax/transient monocular blindness, pure sensory spells, isolated vertigo spells, etc. do not qualify for enrolment given the potential for misdiagnosis of such events).
Patient meets the following:
- At least one 12-lead ECG has already been obtained as part of the routine clinical post-stroke/TIA work-up, and no ECGs have shown any episodes of atrial fibrillation or atrial flutter, and;
- A Holter monitor has already been obtained as part of the routine clinical post-stroke/TIA work-up, and does not show any episodes of atrial fibrillation or atrial flutter ≥30 seconds.
- The patient is being actively investigated for the etiology of the stroke/TIA event and additional cardiac monitoring is desired to screen further for the possibility of occult paroxysmal atrial fibrillation/flutter, i.e. patients selected for this study are those for whom the investigator, in his/her clinical judgment, would consider ordering a repeat Holter monitor as part of clinical care.
The following diagnostic tests have already been completed as part of clinical routine post-stroke/TIA:
- brain imaging with CT or MRI,
- vascular imaging of the extracranial and intracranial circulation with either CT angiography or MR angiography to exclude significant large vessel occlusive disease as the most likely mechanism for the index ischemic event (carotid Doppler ultrasound is acceptable for those presenting with anterior circulation ischemic events),
- transthoracic (or transesophageal) echocardiography to exclude thrombus or other structural heart disease that in the opinion of the investigator is the most likely cause for the stroke/TIA event. [Note: If a baseline echocardiogram cannot be obtained clinically after the index event and prior to study enrollment, then it is acceptable for study purposes for an echocardiogram to be obtained after patient enrollment into the study but prior to the 90-day follow-up visit. Alternatively, an echocardiogram already performed within one year prior to study enrollment may serve as the baseline echocardiogram for study purposes.]
- Age 55 years or older [Note: Participants aged 55-59 years should have imaging confirmation of the index stroke/TIA event with an embolic imaging pattern of acute cerebral ischemia]
- Informed consent from the patient (or from a legally authorized representative if the patient is not competent, e.g. due to stroke-related cognitive impairment, aphasia, or anosognosia).
- The patient is expected to survive at least 6 months.
The patient has a valid provincial health insurance number.
- The index event will be defined as the event leading to medical presentation
Exclusion:
- Any previously documented atrial fibrillation or atrial flutter, i.e. a past history of atrial fibrillation/flutter or atrial fibrillation/flutter detected on ECG, Holter, or telemetry following the index stroke/TIA event (a remote history of transient perioperative atrial fibrillation is not exclusionary
- Exclusively retinal stroke or TIA event.
- A most responsible etiological diagnosis for the qualifying stroke/TIA event has already been determined, i.e. probable small-vessel (lacunar) disease, probable large vessel disease, cervicocephalic artery dissection, venous sinus thrombosis, hypercoagulable states, or other known cause.
- Planned carotid endarterectomy within 90 days.
- Patient is already currently participating in a clinical trial involving an investigational medication or device.*
- Any finding on echocardiography for which there is already an evidence-based indication for long-term anticoagulation (e.g. mechanical heart valve, thrombus, etc.).
- Endocarditis
- Pacemaker or ICD device.
- Patients with known skin reactions to synthetic polymers or to silver. (Some people who display sensitivity to silver jewellery are sensitive to the impurities present in silver alloys and not to the silver itself. These people may participate.)
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Diagnose
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: repeat 24-hour Holter monitor
|
Repeat standard 24-hour Holter Monitor
Andere Namen:
|
|
Experimental: 30-day ambulatory cardiac event monitor
|
Patients will be fitted with dry electrode belt (including cardiac event monitor)and instructed to wear the device for as many hours(waking and sleeping) each day as possible, for a total of 30 days.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Detection of one or more episodes of atrial fibrillation or atrial flutter ≥30 seconds, as assessed at the 90 day follow-up
Zeitfenster: 90 days
|
90 days
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Atrial fibrillation <30 seconds
Zeitfenster: 90 days
|
90 days
|
|
Atrial flutter <30 seconds
Zeitfenster: 90 days
|
90 days
|
|
Non-sustained (>3 beats, <30 seconds) irregular atrial tachyarrhythmia (including brief runs of atrial fibrillation)
Zeitfenster: 90 days
|
90 days
|
|
Proportion of patients in each group that are prescribed oral anticoagulation, as assessed at the 90-day follow-up
Zeitfenster: 90 days
|
90 days
|
|
Patient adherence with 30-day monitoring: average proportion of days wearing the monitor per patient, and the percentage of patients wearing the monitor for >75% of the target period
Zeitfenster: 90 days
|
90 days
|
|
1 and 2-year recurrence of ischemic stroke/TIA, death, hemorrhagic stroke, major adverse bleeding event, detection of atrial fibrillation outside of the study protocol
Zeitfenster: 2 years
|
2 years
|
|
composite endpoint of: (1) AF >30 seconds, (2) non-sustained (>3 beats, <30 seconds) irregular atrial tachyarrhythmia (including brief runs of AF), or (3) atrial flutter.
Zeitfenster: 90 days
|
90 days
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Ermittler
- Hauptermittler: David J Gladstone, MD, PhD, FRCPC, Sunnybrook Health Sciences Centre
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Allgemeine Veröffentlichungen
- Gladstone DJ, Dorian P, Spring M, Panzov V, Mamdani M, Healey JS, Thorpe KE; EMBRACE Steering Committee and Investigators. Atrial premature beats predict atrial fibrillation in cryptogenic stroke: results from the EMBRACE trial. Stroke. 2015 Apr;46(4):936-41. doi: 10.1161/STROKEAHA.115.008714. Epub 2015 Feb 19.
- Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, Vaid H, O'Donnell M, Laupacis A, Cote R, Sharma M, Blakely JA, Shuaib A, Hachinski V, Coutts SB, Sahlas DJ, Teal P, Yip S, Spence JD, Buck B, Verreault S, Casaubon LK, Penn A, Selchen D, Jin A, Howse D, Mehdiratta M, Boyle K, Aviv R, Kapral MK, Mamdani M; EMBRACE Investigators and Coordinators. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014 Jun 26;370(26):2467-77. doi: 10.1056/NEJMoa1311376.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. Mai 2009
Primärer Abschluss (Tatsächlich)
1. April 2014
Studienabschluss (Voraussichtlich)
30. Oktober 2018
Studienanmeldedaten
Zuerst eingereicht
18. Februar 2009
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
18. Februar 2009
Zuerst gepostet (Schätzen)
19. Februar 2009
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
5. Oktober 2018
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
3. Oktober 2018
Zuletzt verifiziert
1. Oktober 2018
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Herzkrankheiten
- Herz-Kreislauf-Erkrankungen
- Gefäßerkrankungen
- Zerebrovaskuläre Erkrankungen
- Erkrankungen des Gehirns
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- Arrhythmien, Herz
- Ischämie des Gehirns
- Ischämie
- Ischämische Attacke, vorübergehend
- Vorhofflimmern
- Vorhofflattern
Andere Studien-ID-Nummern
- Embrace001
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .